Subscribe
Sign in
Home
Archive
Leaderboard
About
The 5 most important ideas for 2026
Seismic shifts are underway in the GLP-1 market
Dec 29, 2025
•
Ashwin Sharma, MD
18
2
Latest
Top
Discussions
Is Your Telehealth Platform Scaring Patients Away?
Design is the overlooked moat in digital health
Dec 16, 2025
•
Ashwin Sharma, MD
5
When Science Fails, and Startups Fly
Novo has cause to be disheartened, while Function Health and GLP-1 consumers in India do not
Nov 25, 2025
•
Ashwin Sharma, MD
18
2
Trump's announcement shifts competition in the GLP-1 market
Who will benefit, and who won’t?
Nov 11, 2025
•
Ashwin Sharma, MD
18
1
3
Why Can't Anyone Stop Compounded GLP-1s?
Because federal, legal, and private forces won't allow it
Nov 2, 2025
•
Ashwin Sharma, MD
25
3
6
What Comes After the GLP-1 Hype?
It's messy, unglamorous stuff involving patients and insurers and crystal balls for pharma
Sep 28, 2025
•
Ashwin Sharma, MD
20
5
3
When GLP-1s become brain drugs
Doors are opening for Alzheimer's patients, for Novo, and for... Regeneron?
Sep 14, 2025
•
Ashwin Sharma, MD
30
3
3
Why Novo Nordisk and Eli Lilly Won't Compete on Price
But they will compete on market access and launch success
Sep 1, 2025
•
Ashwin Sharma, MD
21
5
7
See all
GLP-1 Digest
The GLP-1 newsletter for founders, operators and investors.
Subscribe
Recommendations
The Argument
Jerusalem Demsas
Big Pharma Sharma
Big Pharma Sharma
In-Network
David Ohta
The Gut Group
Dr Arif Hussenbux MBBS
GLP-1 Digest
Subscribe
About
Archive
Recommendations
Sitemap
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts